• Plus Therapeutics reaffirmed 2026 outlook, targeting more than 150 million covered lives for CNSide commercial payer agreements.
• Contracted CNSide coverage reached about 126 million people, up from about 67 million at the start of 2026.
• Forecasts CNSide test volume run rate of 1,250 tests annually by end-2026; 232 tests completed year-to-date, including a record 72 in June.
• ReSPECT-LM expects recommended Phase 2 dose by year-end, based on 12-18 patients; about one-third enrolled with no dose-limiting toxicities observed.
• ReSPECT-GBM expects full enrollment in 2026; 31 of 34 subjects enrolled with three active sites.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the information contained therein.